Latest Conference Articles

Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.

Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.

Eric S. Christenson, MD, discusses efficacy data for copanlisib plus nivolumab in patients with pretreated, MSS metastatic colorectal cancer.

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.

Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.

Deborah J. Wong, MD, PhD, discusses the evaluation of atezolizumab vs placebo after definitive local therapy in high-risk, locally advanced HNSCC.

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

James Knight, MD, discusses the potential launch of a case series of patients with brain-metastatic prostate adenocarcinoma.

Jason Efstathiou, MD, DPhil, discusses the role of tri-modality therapy in patients with muscle-invasive bladder cancer.

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.